Monopar stock gets Buy rating from H.C. Wainwright on positive Wilson disease data

Investing.com - H.C. Wainwright has reiterated a Buy rating and $70.00 price target on Monopar Therapeutics (NASDAQ:MNPR), whose shares have surged nearly 19% in the past week. According to InvestingPro data, analyst targets range from $52 to $162, with a strong consensus recommendation of 1.4 (Buy). The announcement follows new long-term data for ALXN1840 presented at the American Neurological Association Annual Meeting.

The data showed consistent improvements in neurological function over six years, measured by the Unified Wilson Disease Rating Scale (UWDRS) and reported by both patients and clinicians. The pooled dataset combined results from multiple Phase 2 and Phase 3 trials, including more than 255 patients who remained on ALXN1840 for a median of approximately 2.6 years. Monopar, with a market capitalization of $304 million, maintains strong financial health with an impressive current ratio of 33.94, according to InvestingPro analysis.

Treatment-naïve patients with severe disease in the Phase 2 WTX101-201 trial showed the most significant benefit, with 94% of patients improving versus 5% worsening. The Phase 3 WTX101-301 study, which excluded patients with intermediate or severe disease, demonstrated more modest benefits with 45% of patients improving versus 8% worsening.

Crossover data indicated that patients switching from standard of care to ALXN1840 experienced neurological improvement, even among those who had previously worsened on standard treatment. The safety profile remained favorable with only 4.9% of patients reporting any drug-related serious adverse events.

H.C. Wainwright noted that these results position ALXN1840 as a potential "step-change therapy" for Wilson disease, addressing previous concerns raised by AstraZeneca (NASDAQ:AZN) that were now characterized as "an artifact of poor quantification." Based on InvestingPro’s comprehensive analysis, Monopar appears overvalued at current levels, though investors can access 10+ additional ProTips and detailed financial metrics with an InvestingPro subscription to make more informed investment decisions.

In other recent news, Monopar Therapeutics has received significant attention from various research firms. BTIG initiated coverage on Monopar with a Buy rating and set a price target of $87, focusing on the company’s development of ALXN1840, a therapy for Wilson’s Disease. Cantor Fitzgerald reiterated its Overweight rating with a $74 price target, emphasizing the ongoing support from the ALXN team for Monopar’s drug development. H.C. Wainwright also initiated coverage with a Buy rating and a $70 price target, noting the drug’s superior copper mobilization and neurologic benefits in Phase 3 trials. Chardan Capital Markets joined the list by initiating coverage with a Buy rating and a $60 price target, highlighting the potential of Monopar’s late-stage Wilson disease treatment. These recent developments indicate strong analyst confidence in Monopar’s pipeline and its potential impact on treating Wilson’s Disease.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.